Boston Strategic Partners supports poster presentation at the 2017 Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine

(Lake Buena Vista, FL, Dec 2017) – Boston Strategic Partners supported Mallinckrodt in the creation of two posters recently presented at the 16th Annual Pain Medicine Meeting: Leading with Quality. This annual meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA) was held from November 16-18, 2017 at Lake Buena Vista, Florida.

The first poster titled “Clinical and economic outcomes associated with the use of intravenous versus oral acetaminophen for management of acute postoperative pain in obstetrics and gynecology patients”, is based on a retrospective analysis of the Cerner Health Facts® database comparing outcomes of obstetrics and gynecology (Ob/Gyn) surgery patients who received IV APAP for pain management to those who received oral APAP. Postoperative pain management is a key component of successful surgical recovery, which impacts patient’s hospital length of stay (LOS) and medical expenditures. This study found that compared to oral APAP, managing Ob/Gyn surgery pain with IV APAP was associated with shorter LOS and decreased risk for potential opioid-related adverse events (ORADE).

Please find the link to the poster here.

Multimodal analgesia for controlling acute post-surgical pain is a strategy to reduce ORADE, and intravenous acetaminophen (IV APAP) is a component of such regimens. The second study “Patient characteristics associated with the use of intravenous acetaminophen in the postoperative period” sought to identify characteristics of surgical patients who are most likely to receive IV APAP in current practice in a diverse surgical population observed in the large, multi-centered Health Facts® database by Cerner. It was found that while IV APAP is a well-tolerated and effective medication for use in post-surgical pain, its use varies considerably by surgical procedure. Hospital characteristics, particularly geographic location and whether a hospital is urban or rural, are also associated with its administration. Thus, identifying optimal multimodal analgesia regimens may reduce unnecessary variation in practice in the administration of medications for acute post-surgical pain.

Please find the link to the poster here.


About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:

For more information or to schedule a meeting with our team, please email us at

About Mallinckrodt

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit